Overweight ACN with disciplined 3-tranche scale-in; 25% Tranche 1 at $169-170
OVERWEIGHT ACN at $169-170 with 3-tranche scale-in (25%/35%/40%) and $137 hard stop. Valuation floors (11.6x forward P/E, 11.6% FCF yield, 24.4% ROE, 8% capital return yield) are too compelling to Hold, but prior decision pattern (Aug 12 Buy: -1.6% alpha, Aug 14 Hold: -3.4% alpha) demands 25% vs. trader's 35% Tranche 1 sizing. 200 SMA is regime confirmation for Tranche 3, not entry gate. Base case target $195; $195 base case over 3-6 months.
| Position | Action |
|---|---|
| Entry: current levels $169-170 | Tranche 1: 25% of target size (~1.6% portfolio risk) |
| 50 SMA test ($148-155) with RSI >50 and MACD histogram turning up | Tranche 2: 35% of target size |
| Confirmed daily close above $180.14 with volume >5M sustained 3+ sessions | Tranche 3: 40% of target size |
| Partial profit-taking at $180-185 | Target 1: Sell 25% of position |
| Partial profit-taking at $192-203 (Bollinger upper band / 200 SMA retest) | Target 2: Sell 25% of position |
| Full multiple re-rating at $220+ | Target 3: Sell remaining 50% of position |
ACN is a deeply mispriced quality franchise at a textbook inflection point—trading at 13.6x P/E with 24.4% ROE and 11.6% FCF yield while having already completed a 46.5% V-shaped recovery and confirming a medium-term trend change—making HOLD the wrong recommendation when the valuation gap and fundamentals point to a BUY with high conviction.
| Indicator | Value | Signal |
|---|---|---|
| 200 SMA | 203.81 | bearish |
| 50 SMA | 152.06 | bullish |
| 10 EMA | 173.20 | bearish |
| MACD | +7.82 (signal +7.44, histogram +0.39) | neutral |
| RSI | 56.74 | neutral |
| Bollinger Upper Band | 192.76 | bearish |
| Bollinger Lower Band | 137.75 | bullish |
| ATR | 7.80 | neutral |
Support: 137.75 · 152 · 169.75 | Resistance: 173.2 · 180.14 · 192.76 · 203.81
ACN shows a mixed technical picture: the long-term trend remains bearish (price $34 below 200 SMA at $203.81), but the medium-term recovery is intact (price above 50 SMA at $152.06). Short-term momentum is deteriorating with price closing below the 10 EMA ($173.20) for the first time in 8 sessions, MACD histogram compressing rapidly from +1.52 to +0.39, and RSI sliding from 70.64 to 56.74. The recommendation is HOLD — existing longs from June lows should be kept with stops at the 50 SMA ($152), while new positions should wait for either a re-take of $180 with confirmation or a decisive close below $152 for bearish re-entry.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
The June-August 2026 rally was a powerful V-shaped reversal, not a weak bounce in a downtrend, with all medium-term confirmations already triggered
↩ rebuts: “Bear's reliance on 200 SMA as a gating signal”
EV: +38.5% to T2 ($203) from $169 entry · concedes: The bear is correct that the 200 SMA has not been reclaimed—however, the 50 SMA reclaim, MACD zero-line cross, and V-shape reversal are the actual confirmation signals, not lagging mechanical artifacts; The bear is correct that volatility is elevated—2× ATR ≈ $15.60 stop distance confirms vol is real and position sizing must account for it; The biggest bull risk is being wrong about the AI thesis and the business deteriorating—but the evidence (reaccelerating revenue, 26% FCF growth, $9B M&A pipeline) argues against this; Polen and Aoris exits did happen and represent real capital departure from quality-focused funds
ACN's valuation gap is not mispricing but forward-looking market anticipation of earnings deterioration from AI disruption risk, structural margin compression, and an aggressive M&A program creating a goodwill time bomb—the V-recovery is a bear market rally failing in real time, not a new bull trend.
EV: ~$168.35 (slightly below current ~$170 price based on probability-weighted scenarios); stress-tested EV ~$180.63 even with doubled bull case probability (35%) · concedes: If ACN's AI-enabler narrative is real and bookings accelerate materially in Q3/Q4, the bear case weakens; The bull case could play out at higher probability if macro thesis plays out perfectly; 50 SMA reclaim did occur, though this is the weakest moving average signal
→ vs conservative: Waiting for 200 SMA reclaim at $203 means paying 20% more for same asset; that's expensive, not prudent
→ vs conservative: Polen and Aoris exits are lagging indicators from funds that underperformed by 10 percentage points YTD — citing them as warning signs misreads them as contrarian buy signals
→ vs conservative: 85% no-cut probability already priced in at 11.6x multiple; if Fed cuts even once, it's asymmetric upside on top of already-discounted valuation
→ vs neutral: Waiting for breakout above $180 or breakdown below $152 is paralysis; neutral analyst would either chase at $185 with no dry powder or capitulate at $145
→ vs neutral: Neutral HOLD with accumulation bias is essentially same thesis as BUY but with more friction and delay — trader is actually executing what neutral analyst is waiting for
→ vs neutral: At 9% opportunity cost to $185 and 30-50% upside to fair value, waiting means missing significant gains from current levels
Market Cap
$104.0B
Share Price (Implied)
~$170
52-Week High
$291.09
52-Week Low
$118.15
50-Day Moving Avg
$153.01
200-Day Moving Avg
$207.52
Beta
1.07
Dividend Yield
3.69%
Shares Outstanding
~621.9M
P/E (TTM)
13.58x
Forward P/E
11.59x
PEG Ratio
1.29
P/B
3.26x
EV/EBITDA
~9.6x
Revenue (TTM)
$73.10B
Revenue (FY2025)
$69,673M
Revenue Growth (FY2025)
+7.4%
Gross Profit (TTM)
$23.40B
Gross Margin
32.0%
Operating Margin
17.0%
Net Margin
10.7%
EBITDA (TTM)
$12.94B
EBITDA (FY2025)
$11,867M
Net Income (TTM)
$7.79B
Net Income (FY2025)
$7,678M
Diluted EPS (FY2025)
$12.15
Free Cash Flow (TTM)
$12.09B
Free Cash Flow (FY2025)
$10,874M
FCF Yield
~11.6%
FCF Conversion
142%
ROE
24.4%
ROA
10.9%
Total Assets (FY2025)
$65,395M
Cash & Equivalents (FY2025)
$11,479M
Total Debt (FY2025)
$8,183M
Long-Term Debt (FY2025)
$5,034M
Net Cash
+$3.3B
Stockholders' Equity (FY2025)
$31,195M
Current Ratio (FY2025)
1.34
Goodwill & Intangibles (FY2025)
$24,947M
Goodwill / Total Assets
34%
Dividends Paid (FY2025)
$3.70B
Buybacks (FY2025)
$4.62B
Total Capital Return (FY2025)
$8.32B
Acquisitions (FY2025)
$1,471M
CapEx (FY2025)
($600M)
Strengths
Concerns
Accenture is a deep-value, high-quality compounder trading at a multi-year low valuation with a 13.6x P/E and 11.6% FCF yield, while generating exceptional cash flow ($12.1B TTM) and maintaining a strong 24.4% ROE with a net cash position of $3.3B. The depressed valuation reflects market concerns about AI disruption to traditional IT services, though the company demonstrated reacceleration with +7.4% revenue growth in FY2025 and maintains robust capital return discipline ($8.3B returned to shareholders in FY25). Technical weakness (trading below both 50-day and 200-day MAs) suggests caution for trend-followers, but fundamental evidence supports a constructive view for value-oriented investors at current levels.
Macro: The 30-year Treasury yield hit a 19-year high this week amid heavy Treasury supply and oil-driven inflation impulse; the 10-year has followed. Oil prices rose on Trump threats regarding Oman, expiry of US-Iran ceasefire, and Libya pipeline risks. S&P 500, Dow, and Nasdaq all closed lower in a risk-off tone with dollar weakness. Weak US data prints alongside rising yields create a stagflationary mix that historically pressures consulting deal pipelines with a 1–2 quarter lag. Prediction markets price 85% probability of zero Fed rate cuts in 2026, 8% US recession probability by end-2026, and Anthropic at 97% implied probability of best AI model by end-August 2026.